AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 31 min read$PCVXNeutralLow

Wassil Jim sold $96K of PCVX

Wassil Jim (CHIEF OPERATING OFFICER) sold 1,949 shares of Vaxcyte, Inc. (PCVX) at $49.40 on 2026-06-01 under a Rule 10b5-1 trading plan.

Wassil JimJune 3, 2026
AI analysis
Relevance
6/10
Novelty
3/10
Actionability
Low
Sentiment · $PCVX
Neutral
Timing
SEC Form 4 filed June 3, covering a June 1 sale.
Market alignment
Neutral to mildly negative (insider selling), but tempered by 10b5-1 structure.
Why this matters for $PCVX

Insider selling disclosed on SEC Form 4; likely low fundamental signal given 10b5-1 pre-arrangement, but can affect near-term sentiment/positioning.

Relevance context

Vaxcyte COO Wassil Jim sold $96.3K of PCVX shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Price-impact prediction

Limited immediate impact expected; any reaction is likely sentiment-driven and short-lived.

Background

SEC Form 4 reports insider transactions; 10b5-1 plans are pre-arranged to reduce timing-based trading concerns.

Why it matters

The disclosure can modestly influence short-term sentiment, but it is not a fundamental update by itself.

Market relevance

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a durable repricing without additional catalysts.

Market effects

Sector

Minimal; this is company-specific insider disclosure with no stated sector/regulatory catalyst.

Regional

None.

Global

None.

Alternative perspectives

Contrarian view

Because the sale is under a 10b5-1 plan, the market may overreact; the disclosure may not reflect new bearish information.

Overlooked factors

The article provides only the sale size and plan status, not whether other insiders/funds changed positions around the same time.

Key entities

  • issuer
    Vaxcyte, Inc.

    Subject of the insider transaction disclosure (PCVX).

  • officer
    Wassil Jim

    Chief Operating Officer who sold 1,949 shares on June 1 under a 10b5-1 plan.

Read at source← All news

Related articles

MAY 6
$PCVXMed

FMR LLC discloses 11.4% stake in Vaxcyte (NASDAQ: PCVX)

FMR LLC has disclosed an 11.4% stake in Vaxcyte (NASDAQ: PCVX), representing beneficial ownership of 16,451,061.32 shares. This information comes from an Amendment No. 9 to a Schedule 13G/A filing, which details voting and dispositive powers held by FMR LLC and Abigail P. Johnson. The filing is administrative and does not indicate a transaction, but rather clarifies ownership structure and authorities.

Stock Titan2 min
MAY 1
$PCVXMed

Vanguard (PCVX) holds 7.25M Vaxcyte shares, reports 5.03% stake

Vanguard Capital Management has reported a beneficial ownership of 7,252,053 shares of Vaxcyte Inc. common stock, which represents a 5.03% stake in the company. The Schedule 13G filing indicates Vanguard has sole power to dispose of all 7.25 million shares and sole voting power over 985,352 shares. This disclosure, signed on April 30, 2026, reflects a passive investment by the large manager and does not imply any operational changes at Vaxcyte or immediate trading intent.

Stock Titan2 min
APR 8
$PCVXLow

Elvia Cowan registers 3,000-share sale (PCVX) after option exercise

Elvia Cowan has filed a Form 144 to report the proposed sale of 3,000 shares of Vaxcyte, Inc. (PCVX) common stock on April 7, 2026, stemming from an exercise of stock options with cash payment. The filing also details prior sales made by Cowan, including 2,500 shares on March 11, 2026, for $146,481.75 and 1,892 shares on March 17, 2026, for $105,146.20. An expert notes this is a typical procedure for affiliates converting derivatives and registering shares for resale under Rule 144.

Stock Titan2 min
JAN 31
$PCVXMed

Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering

Latham & Watkins LLP advised the underwriters in Vaxcyte, Inc.'s US$550 million public offering of common stock. Vaxcyte, a clinical-stage vaccine innovation company, is selling 11 million shares at US$50 per share, with an option for underwriters to purchase an additional 1.65 million shares. The Latham & Watkins team was led by Shayne Kennedy and Richard Kim, with support on regulatory, IP, and tax matters.

Latham & Watkins LLP2 min
JAN 22
$PCVXMed

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Vaxcyte, Inc. has provided an update on the advancement of its next-generation 31-valent pneumococcal conjugate vaccine (VAX-31) across both adult and infant clinical programs. The company has dosed the first participants in a Phase 3 study for adults, OPUS-2, and plans to initiate another Phase 3 study, OPUS-3, in the first quarter of 2026. For the infant indication, Vaxcyte has completed enrollment in its Phase 2 dose-finding study.

GlobeNewswire3 min